Assessment tools and outcomes in real–world migraine patients eligible for treatment with an anti–calcitonin gene–related peptide antibody

• Published in: 神経治療学 Vol. 41; no. 1; pp. 39 - 48
• Main Authors: Kasai Hideyo, Watanabe Keiko, Yasumoto Taro, Mizuma Keita, Futamura Akinori, Kuroda Takeshi, Yano Satoshi, Hieda Sotaro, Ono Kenjiro, Murakami Hidetomo
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Neurological Therapeutics 2024; 日本神経治療学会
• Subjects: fremanezumab; galcanezumab; migraine; migraine disability assessment; real–world evidence

Real–world clinical outcomes were examined in 96 patients with migraine who were eligible for treatment with anti–calcitonin gene–related peptide (CGRP) antibodies. In 71 patients who received this treatment, three assessment tools (Migraine Disability Assessment Scale (MIDAS), Headache Impact Test...